|
Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb/Medarex; Medison |
|
|
Honoraria - Bristol-Myers Squibb; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medison; MSD Oncology; NeoPharm; Novartis; Roche |
Consulting or Advisory Role - MSD Oncology |
Research Funding - MSD Oncology |